DS Biopharma Announces Receipt of Two Notices of Allowance for U.S. Patent Applications Covering the Manufacture and Methods of Use for its Bioactive Compounds

DUBLIN, June 15, 2015 /PRNewswire/ --

DS Biopharma (DS), a privately held drug discovery and development company, announced today that the United States Patent and Trademark Office (USPTO) has issued two Notices of Allowance for its patent applications covering the manufacture and method of use for its bioactive compounds under development.

U.S. patent application No. 13/688,998, entitled "Compositions comprising 20-carbon Fatty Acids and Methods of Making and Using Same" describes a process for producing compositions comprising 20-carbon fatty acids and methods of using such compositions to treat a wide range of conditions including inflammatory, cardiovascular, respiratory and skin diseases. The allowed claims cover a process for elongating 18-carbon fatty acids to produce a composition comprising 20-carbon fatty acids. Composition and method of use claims for the elongated fatty acids are also allowed.

U.S. patent application No. 13/622,120, entitled "Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETRE and Method of Use Thereof" is generally directed to methods of treating skin diseases and disorders such as Acne or Atopic Dermatitis using compositions comprising fatty acids.

Tien Nghiem, Director of Product Development and Intellectual Property at DS, commented: "These patent allowances provide further strong intellectual property protection for our lead compounds. These patents confirm and validate the DS Biopharma approach to developing novel therapies using its bioactive lipid compounds for unmet medical needs."

Once issued, both patents will provide exclusivity until 2032 and will be significant additions to the DS Biopharma intellectual property portfolio, which consists of five granted patents in the U.S. and a number of pending applications.

About DS Biopharma   

DS Biopharma, headquartered in Dublin, Ireland, is a privately held drug discovery and development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective. DS has developed a proprietary library of bioactive lipids from which it is working on new approaches to treat non-alcoholic steatohepatitis (NASH), atopic dermatitis and other inflammatory and pulmonary disorders.

For more information, visit http://www.dsbiopharma.com

SOURCE DS Biopharma